Alkermes plc. Pre-Tax Income
Alkermes plc. (ALKS) reported Pre-Tax Income of -$1.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Income Statement
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-07-28
- Alkermes plc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$1.88M, a 101.79% decline year-over-year.
- Alkermes plc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was -$61.93M, a 342.95% decline year-over-year.
- Alkermes plc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was $60.38M, a 64.46% decline year-over-year.
- Alkermes plc. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was $100.75M, a 8.60% decline year-over-year.
- Alkermes plc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was $291.45M, a 34.32% decline from fiscal 2024.
- Alkermes plc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was $443.75M, a 5.27% increase from fiscal 2023.
- Alkermes plc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was $421.52M.
- Alkermes plc. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2022 was -$31.13M, a 135.48% decline from fiscal 2021.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month as first filed | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.88M 10-Q · filed 2026-07-28 | -$63.80M 10-Q · filed 2026-07-28 | -$3.42M derived: sum of 3 quarters · filed 2026-07-28 | $97.32M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2026-03-31 | -$61.93M 10-Q · filed 2026-05-05 | -$1.55M derived: sum of 2 quarters · filed 2026-05-05 | $99.20M derived: sum of 3 quarters · filed 2026-05-05 | $204.03M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2025-12-31 | $60.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $161.12M derived: sum of 2 quarters · filed 2026-02-25 | $265.96M derived: sum of 3 quarters · filed 2026-07-28 | $291.45M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $100.75M 10-Q · filed 2025-10-28 | $205.58M derived: sum of 2 quarters · filed 2026-07-28 | $231.07M 10-Q · filed 2025-10-28 | $400.96M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2025-06-30 | $104.84M 10-Q · filed 2026-07-28 | $130.33M 10-Q · filed 2026-07-28 | $300.22M derived: sum of 3 quarters · filed 2026-07-28 | $410.45M derived: sum of 4 quarters · filed 2026-07-28 | ||||
| 2025-03-31 | $25.49M 10-Q · filed 2026-05-05 | $195.38M derived: sum of 2 quarters · filed 2026-05-05 | $305.61M derived: sum of 3 quarters · filed 2026-05-05 | $422.33M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $169.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $280.12M derived: sum of 2 quarters · filed 2026-02-25 | $396.84M derived: sum of 3 quarters · filed 2026-02-25 | $443.75M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $110.23M 10-Q · filed 2025-10-28 | $226.95M derived: sum of 2 quarters · filed 2025-10-28 | $273.86M 10-Q · filed 2025-10-28 | $332.18M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $116.72M 10-Q · filed 2025-07-29 | $163.63M 10-Q · filed 2025-07-29 | $221.95M derived: sum of 3 quarters · filed 2026-02-25 | $314.65M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $46.91M 10-Q · filed 2025-05-01 | $105.23M derived: sum of 2 quarters · filed 2026-02-25 | $197.94M derived: sum of 3 quarters · filed 2026-02-25 | $479.76M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $58.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $151.02M derived: sum of 2 quarters · filed 2026-02-25 | $432.85M derived: sum of 3 quarters · filed 2026-02-25 | $421.52M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $92.71M 10-Q · filed 2024-10-24 | $47.36M 10-Q · filed 2023-10-25 | $374.54M derived: sum of 2 quarters · filed 2024-10-24 | $363.20M 10-Q · filed 2024-10-24 | $239.26M 10-Q · filed 2023-10-25 | $477.69M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-06-30 | $281.83M 10-Q · filed 2024-07-24 | $239.75M 10-Q · filed 2023-07-26 | $270.50M 10-Q · filed 2024-07-24 | $191.90M 10-Q · filed 2023-07-26 | $384.98M derived: sum of 3 quarters · filed 2025-02-12 | $317.62M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-03-31 | -$11.33M 10-Q · filed 2024-05-01 | -$47.85M 10-Q · filed 2023-04-26 | $103.16M derived: sum of 2 quarters · filed 2025-02-12 | $35.79M derived: sum of 3 quarters · filed 2025-02-12 | $2.54M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2022-12-31 | $114.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $47.12M derived: sum of 2 quarters · filed 2025-02-12 | $13.87M derived: sum of 3 quarters · filed 2025-02-12 | -$31.13M 10-K · filed 2025-02-12 | -$167.30M 10-K · filed 2023-02-16 | |||
| 2022-09-30 | -$67.37M 10-Q · filed 2023-10-25 | -$100.62M derived: sum of 2 quarters · filed 2023-10-25 | -$145.62M 10-Q · filed 2023-10-25 | -$18.36M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | -$33.25M 10-Q · filed 2023-07-26 | -$78.25M 10-Q · filed 2023-07-26 | $49.01M derived: sum of 3 quarters · filed 2024-02-21 | $22.48M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | -$45.00M 10-Q · filed 2023-04-26 | $82.26M derived: sum of 2 quarters · filed 2024-02-21 | $55.73M derived: sum of 3 quarters · filed 2024-02-21 | $61.38M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | $127.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $100.72M derived: sum of 2 quarters · filed 2024-02-21 | $106.38M derived: sum of 3 quarters · filed 2024-02-21 | $87.73M 10-K · filed 2024-02-21 | -$39.31M 10-K · filed 2022-02-16 | |||
| 2021-09-30 | -$26.54M 10-Q · filed 2022-11-02 | -$20.88M derived: sum of 2 quarters · filed 2022-11-02 | -$39.53M 10-Q · filed 2022-11-02 | -$81.18M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-06-30 | $5.66M 10-Q · filed 2022-07-27 | -$13.00M 10-Q · filed 2022-07-27 | -$54.64M derived: sum of 3 quarters · filed 2023-02-16 | -$52.45M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2021-03-31 | -$18.65M 10-Q · filed 2022-04-27 | -$60.30M derived: sum of 2 quarters · filed 2023-02-16 | -$58.11M derived: sum of 3 quarters · filed 2023-02-16 | -$83.86M derived: sum of 4 quarters · filed 2023-02-16 | ||||
| 2020-12-31 | -$41.65M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | -$39.45M derived: sum of 2 quarters · filed 2023-02-16 | -$65.21M derived: sum of 3 quarters · filed 2023-02-16 | -$96.54M 10-K · filed 2023-02-16 | ||||
| 2020-09-30 | $2.19M 10-Q · filed 2020-10-29 | -$23.57M derived: sum of 2 quarters · filed 2020-10-29 | -$54.89M 10-Q · filed 2020-10-29 | -$57.45M derived: sum of 4 quarters · filed 2022-02-16 | ||||
| 2020-06-30 | -$25.76M 10-Q · filed 2020-07-29 | -$57.08M 10-Q · filed 2020-07-29 | -$59.64M derived: sum of 3 quarters · filed 2022-02-16 | -$113.50M derived: sum of 4 quarters · filed 2022-02-16 | ||||
| 2020-03-31 | -$31.32M 10-Q · filed 2020-04-29 | -$33.88M derived: sum of 2 quarters · filed 2022-02-16 | -$87.74M derived: sum of 3 quarters · filed 2022-02-16 | -$128.13M derived: sum of 4 quarters · filed 2022-02-16 | ||||
| 2019-12-31 | -$2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | -$56.42M derived: sum of 2 quarters · filed 2022-02-16 | -$96.80M derived: sum of 3 quarters · filed 2022-02-16 | -$197.06M 10-K · filed 2022-02-16 | ||||
| 2019-09-30 | -$53.86M 10-Q · filed 2020-10-29 | -$94.25M derived: sum of 2 quarters · filed 2020-10-29 | -$194.50M 10-Q · filed 2020-10-29 | |||||
| 2019-06-30 | -$40.39M 10-Q · filed 2020-07-29 | -$140.64M 10-Q · filed 2020-07-29 | ||||||
| 2019-03-31 | -$100.25M 10-Q · filed 2020-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |